Cellectis S.A. ADR (CLLS) Stock Price, Quote & News

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence,...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 81 69 16 00

Website: www.cellectis.com

Address:

8, rue de la Croix Jarry, Paris, France

SuperGreenToday May. 27 at 12:53 AM

$CLLS Share Price: $3.67 Contract Selected: Nov 20, 2026 $2.5 Calls Buy Zone: $1.99 – $2.46 Target Zone: $3.33 – $4.07 Potential Upside: 58% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

PennyScam May. 20 at 1:30 PM

$CLLS LTC deal is just another frivolous suit. It’s an another he said she said bullshit claim to get at that cash. Argh… Just another money grab eh RK. At the same time there could be some credibility. Licensing can be a fickle thing. It can also be simply adjusted to rectify. This shit happens all the time. I see this as posturing. Someone woke up, saw the glitch with some good hard legal beagle work and here we stand. Cellectis runs a tight ship. I see this as nothing. But Cellectis is my Baby. And no one puts Baby in the corner.

1 · Reply

mikefbi May. 14 at 7:54 PM

$CLLS slow and steady

0 · Reply

rlkloehn May. 13 at 8:59 PM

$CLLS On April 20, 2026, Life Technologies Corporation ("LTC"), a subsidiary of Thermo Fisher, claimed to terminate licensing agreements between LTC and Cellectis in 2014, which grant Cellectis non-exclusive rights under certain patents, namely Halle Patent Therapeutic License, Halle Patent Research License and GeneArt and Seamless Cloning Patent Therapeutic License (the "LTC Agreements"). This alleged termination follows TFS's allegations that we did not comply with our obligations under the LTC Agreements, as previously indicated. Simultaneously, LTC brought arbitration proceedings before the American Arbitration Association, designating Cellectis S.A. and Cellectis Bioresearch, Inc. as defendants. LTC's arbitration request alleges that Cellectis violated the LTC Agreements, by underpaying sub-licensing fees and more generally by not complying with our obligations under the LTC Agreements.

1 · Reply

rlkloehn May. 12 at 6:33 PM

$CLLS Cellectis announced two presentations at the European Hematology Association (EHA) 2026 congress: 🔵 Lasme-cel - Oral presentation | June 13 The full Phase 1 BALLI-01 dataset highlight the promising safety profile and response rates in patients with r/r B-ALL, who have relapsed following multiple prior targeted therapies including autologous CD19 CAR-T. These data form the basis for our pivotal Phase 2 program, currently recruiting in Europe and North America. ➡️ First interim pivotal Phase 2 analysis expected in Q4 2026. 🔵 Eti-cel - Poster presentation | June 13 Early mechanistic insights from the NATHALI-01 study in r/r B-NHL, exploring how lymphodepletion optimization drives cellular expansion and clinical response for our dual-targeting CD20×CD22 allogeneic CAR-T. ➡️ Full Phase 1 data expected in Q4 2026.

0 · Reply

PyroMatic May. 5 at 4:17 AM

$CLLS watching for bottom.

0 · Reply

rlkloehn Apr. 28 at 9:09 AM

$CLLS ASGCT abstract 3414 In vivo targeted gene insertion using AAV and LNP formulated TALEN mRNA drives phenylalanine lowering and metabolic rescue in a PKU model 1Alexion Pharmaceuticals, Cambridge, MA, United States, 2Cellectis, New York, NY, United States, 3Astrazeneca 4Cellectis, Paris, France, 5Alexion Pharmaceuticals, Boston, MA, Phenylketonuria (PKU) is caused by inherited deficiency of phenylalanine hydroxylase (PAH), most often due to missense PAH mutations, impairing conversion of phenylalanine to tyrosine. Elevated phenylalanine in blood and brain causes neurotoxicity and developmental impairment. Current standard of care including life-long dietary protein restriction and approved therapies such as sapropterin and pegvaliase are either ineffective or carry black box warnings, underscoring the need for new therapies.

0 · Reply

rlkloehn Apr. 28 at 2:52 AM

$CLLS Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting May 11-15, in Boston. The data will be presented in a poster: Title: TALE-based epigenetic modulators show sustained knock-down of target genes in T-cells and HEPG2 via a high-throughput multiplex screening platform The abstract is published on the ASGCT website. The poster will be available on Cellectis’ website on the presentation day, Wednesday May 13, 2026 at 5 pm ET.

0 · Reply

rlkloehn Apr. 23 at 3:08 AM

$CLLS quite the video https://www.linkedin.com/posts/cellectis_car-t-cells-killing-cancer-cells-activity-7452721909844189184-COYR

1 · Reply

PennyScam Apr. 18 at 10:20 PM

$CLLS Great stuff. On the rise. Nice. Crazy K

0 · Reply

Market Cap	310.05M
Revenue (ttm)	79.59M
Net Income (ttm)	-67.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-84.92%
Debt to Equity Ratio	1.28

Volume	101,900
Avg Vol	36,578
Day's Range	N/A - N/A
Shares Out	100.34M
Stochastic %K	14%
Beta	2.86
Analysts	Strong Sell
Price Target	$7.60